18F-FET-PET/MRI vs Standard MRI Alone for Stereotactic RadioTherapy Planning for High Grade Brain Gliomas

NAActive, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2026

Conditions
Glioma, Malignant
Interventions
DIAGNOSTIC_TEST

0-(2-18F-Fluoroethyl)-L-Tyrosine

0-(2-18F-Fluoroethyl)-L-Tyrosine positron emission tomography (FET) is an amino acid agent derived from tyrosine that is able to cross the blood brain barrier. It has been studied primarily in diagnosis and detection of tumor recurrence in glioblastomas with emerging evidence for its use in brain metastases. Compared to conventional MRI, FET-PET has been shown to delineate geographically distinct tumor volume in newly diagnosed GBM suggesting the complementarity of the two modalities.

Trial Locations (1)

M4N2M5

Sunnybrook Health Sciences Centre, Toronto

All Listed Sponsors
lead

Sunnybrook Health Sciences Centre

OTHER